ESTRO 2025 - Abstract Book

S861

Clinical - Gynaecology

ESTRO 2025

Conclusion: In our experience, using higher median doses than in the MITO retrospective trials, we observed high rate of local complete response and persistent long term LRFS. Patients with complete response after SBRT had a statistically significant higher rate of DFS, than those with partial/ stable response or progressive disease, thus demonstrating that local control in oligometastatic patients from gynecological cancers is a relevant objective. Prospective studies are needed to confirm these results.

Keywords: SBRT, oligometastasis

References: 1. Macchia G et al. A Large, Multicenter, Retrospective Study on Efficacy and Safety of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study):A Collaboration of MITO, AIRO GYN, and MaNGO Groups (2020) 2. Macchia et al, Stereotactic body radiotherapy in oligometastatic cervical cancer (MITO-RT2/RAD study):a collaboration of MITO, AIRO GYN, and MaNGO groups (2022) 3. Macchia G et al. Efficacy and Safety of Stereotactic Body Radiation Therapy in Oligometastatic Uterine Cancer (MITO RT2/RAD):A Large, Real-World Study in Collaboration With Italian Association of Radiation Oncology, Multicenter Italian Trials in Ovarian Cancer, and Mario Negri Gynecologic Oncology Group Groups (2023)

3773

Digital Poster Unsupervised Clustering Analysis of Laboratory Data and Inflammatory Indices in Locally Advanced Cervical Cancer Treated with Chemoradiation Federica Medici 1,2 , Martina Ferioli 3 , Arina A Zamfir 4 , Milly Buwenge 1 , Gabriella Macchia 5 , Francesco Deodato 5 , Donato Pezzulla 5 , Carmela Romano 5 , Paolo Castellucci 6 , Luca Tagliaferri 7 , Anna M Perrone 8,1 , Pierandrea De Iaco 8,1 , Lidia Strigari 9 , Alberto Bazzocchi 10 , Stefania M.R. Rizzo 11 , Alessandra Arcelli 4 , Stefano Fanti 6 , Alessio Giuseppe Morganti 1,3 , Savino Cilla 12 1 Department of Medical and Surgical Sciences (DIMEC, Alma Mater Studiorum University of Bologna, Bologna, Italy. 2 Département de Radiothérapie, Gustave Roussy, Paris, France. 3 Radiation Oncology, Azienda Ospedaliero Universitaria di Ferrara, Ferrara, Italy. 4 Radiation Oncology, IRCCS Azienda Ospedaliero—Universitaria di Bologna, Bologna, Italy. 5 Radiotherapy Unit, Gemelli Molise Hospital, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Campobasso, Italy. 6 Nuclear Medicine, IRCCS Azienda Ospedaliero—Universitaria di Bologna, Bologna, Italy. 7 Dipartimento Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. 8 Division of Gynecologic Oncology, IRCCS Azienda Ospedaliero— Universitaria di Bologna, Bologna, Italy. 9 Medical Physics, IRCCS Azienda Ospedaliero—Universitaria di Bologna,